The tumor uptake of [177Lu]Lu-PSMA-617 peaked at 1h post-injection (16.5±2.46 %IA/g), and the tumor uptake level was reduced slowly over time (11.0±2.12 %IA/g at 72h post-injection). This evidence concerns the gene FOLH1 and neoplasm.